Eli Lilly and Company (LLY) NYSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
Lilly Corporate Center
Indianapolis, IN 46285
United States of America (the)
Phone
317 276 2000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
47000
First IPO Date
June 01, 1972
| Name | Title | Pay | Year Born |
| David A. Ricks | Chairman & CEO | 8.92M | 1968 |
| Diogo Rau | Executive VP and Chief Information & Digital Officer | 1.06M | 1975 |
| Patrik Jonsson | Executive VP & President of Lilly International | 1.67M | 1967 |
| Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development | 3M | 1985 |
| Lucas E. Montarce | Executive Vice President & Chief Financial Officer | 3.24M | 1978 |
| Anat Hakim | Executive Vice President, General Counsel & Secretary | 3.34M | 1969 |
| Daniel Skovronsky | Chief Scientific & Product Officer and President of Lilly Research Laboratories | 4.9M | 1974 |
| Donald A. Zakrowski | Senior Vice President of Finance & Chief Accounting Officer | 0 | N/A |
| Eric Dozier | Executive Vice President & Chief People Officer | 0 | 1967 |
| Frank Cunningham | Senior Vice President of Global Value & Access | 0 | N/A |
| Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities | 0 | 1975 |
| Michael Czapar | Director of Investor Relations | 0 | N/A |
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.